Immunic, Inc. filed a Form 8-K with the SEC on November 5, 2026, disclosing that the company hosted a Progressive Multiple Sclerosis Research and Development Day webinar and attaching the accompanying presentation as an exhibit.

Key Highlights

  • Event date and time: The PMS R&D Day webinar took place on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference, according to the filing.
  • Presentation attached: A presentation dated November 5, 2026, was filed as Exhibit 99.1 and incorporated by reference into the Current Report.
  • Regulation FD: The disclosure was made under Item 7.01, Regulation FD Disclosure.
  • Key focus area: The filing identifies vidofludimus calcium as the company's development candidate discussed in relation to progressive multiple sclerosis.
  • Forward-looking statements: The filing contains forward-looking statements that the company identifies as subject to substantial risks and uncertainties under the Private Securities Litigation Reform Act of 1995.
  • Signed by: The report was signed by Erik Lundgren, Chief Executive Officer, on November 5, 2026.

Immunic's Progressive MS R&D Day: What the Filing Covers

Immunic, Inc. (NASDAQ:IMUX) filed a Current Report on Form 8-K on November 5, 2026, disclosing the hosting of a Progressive Multiple Sclerosis Research and Development Day webinar. According to the filing, the event ran from 12:30 p.m. to 2:00 p.m. ET via video conference on the same date as the filing. The presentation used during the event was attached as Exhibit 99.1 and incorporated by reference into the report.

The filing was made under Item 7.01 (Regulation FD Disclosure), and the company noted that the information in that item and in Exhibit 99.1 "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934." Topics referenced in the forward-looking statements section of the filing include the development of vidofludimus calcium, its potential to target progressive multiple sclerosis, the feasibility of advancing the compound to a confirmatory phase 3 clinical trial, and anticipated clinical milestones and regulatory approvals. The company stated these are the company's own forward-looking statements and are subject to its cautionary language.

The filing references the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, as a source for additional risk factor disclosures. Immunic expressly disclaimed any intent or obligation to update the forward-looking statements made in the report or presentation after the date they were made.

What Was Disclosed

Immunic, Inc. disclosed via Form 8-K that it hosted a PMS R&D Day webinar on November 5, 2026, and filed the associated investor presentation as Exhibit 99.1 under Regulation FD. The report was signed by CEO Erik Lundgren.